Ann: Starpharma Presents at Bell Potter Conference, page-10

It’s funny that just because Merck continue to feature in ASX Investor presentations you think that it’s full steam ahead in relation to the Starpharma / Merck ADC collaboration two years on …. As I pointed out to you recently in the below post, that worked out so well for us in relation to the Elly Lilly partnership extension where they featured in ASX documentation for years …. until suddenly they didn’t


….. and of course let’s not forget Merck recently committed up to $22 billion for ADCs with Daiichi after their agreement extension date to 10th Aug 2023 with Starpharma went by with nothing further from JF & Co. on the matter being announced via the ASX …. but hey go on believing that Merck are serious about Starpharma ADCs if if makes you feel better ……… IMHO Merck aren’t interested in Starpharma ADCs and that is why they have committed up to $22 billion elsewhere for ADC research - just sayin’


https://hotcopper.com.au/threads/an...ns-conference.7658347/page-6?post_id=70553617

https://www.reuters.com/business/he...llaboration-sankyos-antibody-drug-2023-10-19/

Merck signs $5.5 billion deal with Daiichi for cancer therapy development

• Deal will see Merck pay $5.5 bln, and potentially up to $22 bln
• ADC drugs designed to target cancer
• Japanese firm has six ADC candidates in pipeline
• Daiichi Sankyo shares surge 12% in early trading